386
Participants
Start Date
September 30, 2000
Primary Completion Date
September 30, 2003
Study Completion Date
September 30, 2003
Asacol 800 mg (mesalamine)
tablets, 4.8 g/day for 6 weeks, 2 - 800 mg Asacol tablets and 2 placebo tablets 3 times daily
Asacol 400 mg (mesalamine)
tablets, 2.4 g/day for 6 weeks, 2 - 400 mg Asacol tablets and 2 placebo tablets 3 times daily
Research Site, New York
Long Island Clinical Research Associates, Great Neck
Research Site, Forest Hills
Research Site, Altoona
Research Site, Hanover
Metropolitan Gastroenterology Group, Chevy Chase
Research Site, Baltimore
Digestive Disease Associates, Baltimore
Digestive Disorders Associates, Annapolis
Research Site, Fairfax
Research Site, Fredericksburg
Charlottesville Medical Research, Charlottesville
Richmond GI Research, Richmond
Research Site, Raleigh
Carolinas Digestive Health Associates, Charlotte
Research Site, Statesville
Southeast Research Associates, Marietta
Research Site, Maitland
Center for GI Disorders, Hollywood
Research Site, Zephyrhills
Advanced Gastroenterology Associates, Palm Harbor
Community Clinical Trials, Orange
Regional Research Institute, Jackson
Research Site, Columbus
Consultants for Clinical Research, Cincinnati
Research Site, Cincinnati
GI & Liver Consultants, Dayton
Henry Ford Hospital, Detroit
Wisconsin Center for Advanced Research, Milwaukee
Mayo Clinic, Rochester
University of Chicago Medical Center, Chicago
GI Research, Metairie
Louisiana Research Center, Shreveport
Research Site, Oklahoma City
Research Site, Tulsa
Research Site, Dallas
Research Site, Temple
Research Site, Houston
Houston Medical Research Associates, Houston
Research Site, Austin
Research Site, Arvada
Research Site, Englewood
Research Site, Ogden
Mayo Clinic Scottsdale, Scottsdale
Research Site, Los Angeles
Sharp Rees-Stealy Medical Group, San Diego
AGMG Clinical Research, Anaheim
AGMG Clinical Research, Orange
Research Site, Sacramento
West Hills Gastroenterology Group, Portland
Research Site, Spokane
Center for Medical Research, LLC, Manchester
Brigham & Women's Hospital, Boston
PharmaTrials, Inc., Hillsborough
Research Site, Richmond
Research Site, Toronto
University of Puerto Rico, School of Medicine, San Juan
Lead Sponsor
Warner Chilcott
INDUSTRY